Democrats have introduced a bill that would allow anyone over age 50 to buy into Medicare; an FDA advisory panel has endorsed a ketamine-like depression drug; and the EPA is set to limit the amount of manmade chemicals allowed in drinking water.
On Wednesday, House and Senate Democrats introduced legislation that would allow anyone over age 50 to buy into Medicare. According to POLITICO, the bill sponsors said that the plan will pay for itself with the premiums from new enrollees and more of the money collected would pay for patient care because of “the relative lack of overhead and profit requirements in Medicare compared to the private insurance market.”
An FDA advisory panel has endorsed the experimental medication esketamine for depression. Determining that the benefits outweigh the risks, the panel voted 15-2 in favor of the ketamine-like drug. If the drug, manufactured by Johnson & Johnson, is approved, it would be the first major depression treatment approved in decades, according to STAT News. Some experts have expressed concern that the drug has a high potential for abuse because ketamine is often abused.
The EPA is expected to announce today that it will limit how much toxic chemicals from cookware and carpeting are allowed in drinking water, reported Reuters. The group of chemicals, known as PFAS, have been linked to cancer, liver and thyroid damage, and other health effects. HHS’ Agency for Toxic Substances and Disease Registry said the risk level for exposure to these chemicals should be at least 7 to 10 times lower than the threshold currently recommended by the EPA.
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen